According to a review of previous studies, mutations in TET2 have been identified in 47%-100% of AITL cases, a prevalence significantly higher than the 14.6%-38% observed in PTCL-NOS [11]. Here, TET2 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.